This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

IOP Reduction After Anecortave Acetate Injection in Glaucoma Patients

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified September 2007 by Federal University of São Paulo.
Recruitment status was:  Active, not recruiting
Alcon Research
Information provided by:
Federal University of São Paulo Identifier:
First received: September 20, 2007
Last updated: September 21, 2007
Last verified: September 2007
Introduction: Ocular administration of glucocorticoids is a common and effective treatment for several ocular diseases. However it is often complicated with the elevation of intraocular pressure (IOP). Anecortave acetate (AA) is an analog of cortisol acetate and lacks the typical anti-inflammatory and immunosuppressive properties of glucocorticoids. The effect of its anterior juxtascleral depot (AJD) injection has been evaluated in cases of glaucoma caused by intravitreal triamcinolone acetonide, presenting impressive results. The purpose of this study is to evaluate the efficacy and safety of the AA injection as a possible antiglaucoma treatment alternative. Methods: A prospective clinical study will be carried out including 30 glaucoma patients (30 eyes). After inclusion each patient will receive a single AJD injection of 30 mg of AA in the selected eye. Main outcome measure include: intraocular pressure at 1st day, 7th day, 1st, 2nd and 3rd months.

Condition Intervention
Glaucoma Intraocular Pressure Drug: Anterior Juxtascleral Depot of Anecortave Acetate

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Anterior Juxtascleral Depot of Anecortave Acetate: Intraocular Pressure Reduction in Glaucoma Patients

Resource links provided by NLM:

Further study details as provided by Federal University of São Paulo:

Primary Outcome Measures:
  • Intraocular pressure [ Time Frame: Procedure ]

Secondary Outcome Measures:
  • Visual Acuity; side effects (biomicroscopy exam) [ Time Frame: Post treatment ]

Enrollment: 30
Study Start Date: August 2007

Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Advanced glaucoma cases with surgery or cyclophotocoagulation indication (IOP over 25 mmHg)
  • Patients should be under maximum tolerated medication
  • Low best corrected visual acuity (worse than 20/100)

Exclusion Criteria:

  • Under 18 or over 80
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00533962

São Paulo
São Paulo, Brazil, 01404-001
Sponsors and Collaborators
Federal University of São Paulo
Alcon Research
Study Director: Tiago Prata Federal University of São Paulo
  More Information Identifier: NCT00533962     History of Changes
Other Study ID Numbers: C-01
Study First Received: September 20, 2007
Last Updated: September 21, 2007

Keywords provided by Federal University of São Paulo:
Anecortave Acetate
Intraocular pressure
Advanced glaucoma cases with uncontrolled IOP

Additional relevant MeSH terms:
Ocular Hypertension
Eye Diseases
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Antineoplastic Agents processed this record on August 18, 2017